InvestorsHub Logo
Followers 211
Posts 32237
Boards Moderated 1
Alias Born 06/30/2009

Re: Minnesinger post# 357886

Tuesday, 05/04/2021 8:21:17 AM

Tuesday, May 04, 2021 8:21:17 AM

Post# of 403222
Help me understand, please.
Earlier you said "I find their endorsement of Brilacidin as 'a most potent drug against SARS-CoV-2 than the known antiviral drugs' compelling".

Here you are saying: "Microbial Pathogenesis is hardly a 'prestigious' journal. In fact, it's an open-access journal. For those who don't know what an open-access journal is, it's where the authors pay to publish."

Does that make their endorsement less compelling?



"Oh yeah, Viruses is open access, too:
https://www.mdpi.com/journal/viruses "

Forgive my ignorance but does that mean that this was paid for by the authors (I wonder who, exactly)?
https://www.mdpi.com/search?q=brilacidin&journal=viruses


(This was interesting: "Cited by 1 | Viewed by 6336")


ps. Dug around on the mdpi website:
"open access publication is supported by the authors' institutes or research funding agencies by payment of a comparatively low Article Processing Charge (APC) for accepted articles."
The APC for Viruses is 2200 (Swiss Francs, CHF).
(converts to ~$2400US today)
https://www.mdpi.com/about/apc

Seems pretty insignificant.


I'm tryin ta think but nuttin happens......Curly

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News